Dataset
Naltrexone; LC-ESI-Q; MS; POS; 45 V
Chemical Information
| InChI | InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1 |
|---|---|
| SMILES | Oc(c6)c(O5)c(c(c6)3)C(C1)(C45)C(O)(CCC(=O)4)C(C3)N(CC(C2)C2)C1 |
| InChI Key | DQCKKXVULJGBQN-XFWGSAIBSA-N |
| Molecular Formula | C20H23NO4 |
| Exact Mass | 341.163 g/mol |
Data and Resources
Metadata Information
| Field | Value |
|---|---|
| DOI | |
| License URL | https://creativecommons.org/licenses/by-nc/4.0 |
| Source | https://massbank.eu/MassBank/RecordDisplay?id=MSBNK-Waters-WA000764 |
| Version | |
| Author | |
| Maintainer | |
| Language | |
| MetadataPublished | 2016-01-19 |
| Related Molecule |
|
| Field | Value |
|---|---|
| Measurement Technique | liquid chromatography-mass spectrometry |
| Measurement Variables |
| Data-Source Molecule ID | Data-Source |
|---|---|
| CHEMBL19019 | ChEMBL |
| 7465 | ChEBI |
| DB00704 | DrugBank |
| C07253 | KEGG Ligand |
| CB9394737 | ChemicalBook |
| DTXSID4046313 | EPA CompTox Dashboard |
| REVIA | clinicaltrials |
| ZINC000000001773 | ZINC |
| 1639 | Guide to Pharmacology |
| J9.044A | Nikkaji |
| CETQAW | CCDC |
| 50000787 | BindingDB |
| 60212 | BindingDB |
| NALTREXONE | DailyMed |
| REVIA | rxnorm |
| NALTREXONE | rxnorm |
| NALTREXONE HYDROCHLORIDE | rxnorm |
| VIVITROL | rxnorm |
| EN-1639A | clinicaltrials |
| VIVITROL | clinicaltrials |
| NALTREXONE | clinicaltrials |
| NALTREXONE HYDROCHLORIDE | clinicaltrials |
| TREXAN | clinicaltrials |
| 1765 | DrugCentral |
| SCHEMBL34681 | SureChEMBL |
| MCULE-7032963403 | Mcule |
| 5360515 | PubChem |
| 15882 | Brenda |
| naltrexone | DailyMed |
| HMDB0014842 | Human Metabolome Database |
| PD010071 | ProbesDrugs |
| 5S6W795CQM | FDA SRS |
| LSM-3962 | LINCS |
| 14875729 | PubChem: Thomson Pharma |
| 14753731 | PubChem: Thomson Pharma |
| PA450588 | PharmGKB |
| 16590-41-3 | ACToR |
| 8699294 | eMolecules |
| The data in this table is sourced from UniChem at EBI. | |